Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice

dc.contributor.authorRosenman, Marc B.
dc.contributor.authorDecker, Brian
dc.contributor.authorLevy, Kenneth D.
dc.contributor.authorHolmes, Ann M.
dc.contributor.authorPratt, Victoria M.
dc.contributor.authorEadon, Michael T.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2021-08-09T22:51:35Z
dc.date.available2021-08-09T22:51:35Z
dc.date.issued2017-01-01
dc.description.abstractObjectives: Implementing new programs to support precision medicine in clinical settings is a complex endeavor. We describe challenges and potential solutions based on the Indiana GENomics Implementation: an Opportunity for the Underserved (INGenious) program at Eskenazi Health-one of six sites supported by the Implementing GeNomics In pracTicE network grant of the National Institutes of Health/National Human Genome Research Institute. INGenious is an implementation of a panel of genomic tests. Methods: We conducted a descriptive case study of the implementation of this pharmacogenomics program, which has a wide scope (14 genes, 27 medications) and a diverse population (patients who often have multiple chronic illnesses, in a large urban safety-net hospital and its outpatient clinics). Challenges: We placed the clinical pharmacogenomics implementation challenges into six categories: patient education and engagement in care decision making; clinician education and changes in standards of care; integration of technology into electronic health record systems; translational and implementation sciences in real-world clinical environments; regulatory and reimbursement considerations, and challenges in measuring outcomes. A cross-cutting theme was the need for careful attention to workflow. Our clinical setting, a safety-net health care system, presented some distinctive challenges. Patients often had multiple chronic illnesses and sometimes were taking more than one pharmacogenomics-relevant medication. Reaching patients for recruitment or follow-up was another challenge. Conclusions: New, large-scale endeavors in health care are challenging. A description of the challenges that we encountered and the approaches that we adopted to address them may provide insights for those who implement and study innovations in other health care systems.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationRosenman, M. B., Decker, B., Levy, K. D., Holmes, A. M., Pratt, V. M., & Eadon, M. T. (2017). Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice. Value in Health, 20(1), 54–59. https://doi.org/10.1016/j.jval.2016.08.727en_US
dc.identifier.issn1098-3015, 1524-4733en_US
dc.identifier.urihttps://hdl.handle.net/1805/26426
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.isversionofValue in Healthen_US
dc.relation.journalValue in Healthen_US
dc.sourcePMCen_US
dc.subjectDecision Support Systemsen_US
dc.subjectPrecision Medicineen_US
dc.subjectElectronic Health Recordsen_US
dc.subjectclinical decision supporten_US
dc.subjectpharmacogenomicsen_US
dc.titleLessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practiceen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-891631.pdf
Size:
72.03 KB
Format:
Adobe Portable Document Format
Description:
Author's manuscript
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: